肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2008年
5期
316-318,321
,共4页
周陈华%陈勇%叶鸿%王宝强%陈华津
週陳華%陳勇%葉鴻%王寶彊%陳華津
주진화%진용%협홍%왕보강%진화진
癌,非小细胞肺%放射治疗%抗肿瘤联合化疗方案
癌,非小細胞肺%放射治療%抗腫瘤聯閤化療方案
암,비소세포폐%방사치료%항종류연합화료방안
Carcinoma,non-small-cell lung%Radiotherapy%Antineoplastic combined chemotherapy protocols
目的 探讨放化疗综合治疗加参芪扶正注射液治疗非小细胞肺癌(NSCLC)的疗效和毒副作用.方法 2004年6月至2006年6月,将放化疗综合治疗NSCLC 58例,随机分为两组:两组患者均先给予2个周期的NP方案作诱导化疗[长春瑞滨(NVB)25 mg/m2,第1天、第8天;顺铂(DDP)30 mg/m2,第1天至第3天],3周为1个周期;第2个周期化疗结束后开始放疗,采用常规分割,6～15 MV-X线,DT60 Gy,30次,6周完成.治疗组在放化疗期间加用参芪扶正注射液250 ml,每天1次,21 d为1个周期,2个周期为1个疗程.对照组给予一般支持治疗.两组患者在放疗结束后1周再用NP方案化疗2个周期.比较两组的临床疗效、不良反应、生活质量、免疫功能.结果 治疗组完全缓解率、部分缓解率、总有效率分别为16.7%、60.0%、76.7%;对照组分别为10.7%、50.0%、60.7%.治疗组0.5、1、2年生存率分别为96.7%、65.2%、45.0%;对照组分别为89.3%、48.0%、35.1%.两组比较差异无统计学意义(P＞0.05).两组患者的临床症状、生活质量、免疫功能改善情况比较,差异有统计学意义(P＜0.05).结论 放化疗加参芪扶正注射液综合治疗NSCLC能改善患者的临床症状、生活质量、免疫功能和减轻放化疗的不良反应,但未能提高患者的生存率.
目的 探討放化療綜閤治療加參芪扶正註射液治療非小細胞肺癌(NSCLC)的療效和毒副作用.方法 2004年6月至2006年6月,將放化療綜閤治療NSCLC 58例,隨機分為兩組:兩組患者均先給予2箇週期的NP方案作誘導化療[長春瑞濱(NVB)25 mg/m2,第1天、第8天;順鉑(DDP)30 mg/m2,第1天至第3天],3週為1箇週期;第2箇週期化療結束後開始放療,採用常規分割,6～15 MV-X線,DT60 Gy,30次,6週完成.治療組在放化療期間加用參芪扶正註射液250 ml,每天1次,21 d為1箇週期,2箇週期為1箇療程.對照組給予一般支持治療.兩組患者在放療結束後1週再用NP方案化療2箇週期.比較兩組的臨床療效、不良反應、生活質量、免疫功能.結果 治療組完全緩解率、部分緩解率、總有效率分彆為16.7%、60.0%、76.7%;對照組分彆為10.7%、50.0%、60.7%.治療組0.5、1、2年生存率分彆為96.7%、65.2%、45.0%;對照組分彆為89.3%、48.0%、35.1%.兩組比較差異無統計學意義(P＞0.05).兩組患者的臨床癥狀、生活質量、免疫功能改善情況比較,差異有統計學意義(P＜0.05).結論 放化療加參芪扶正註射液綜閤治療NSCLC能改善患者的臨床癥狀、生活質量、免疫功能和減輕放化療的不良反應,但未能提高患者的生存率.
목적 탐토방화료종합치료가삼기부정주사액치료비소세포폐암(NSCLC)적료효화독부작용.방법 2004년6월지2006년6월,장방화료종합치료NSCLC 58례,수궤분위량조:량조환자균선급여2개주기적NP방안작유도화료[장춘서빈(NVB)25 mg/m2,제1천、제8천;순박(DDP)30 mg/m2,제1천지제3천],3주위1개주기;제2개주기화료결속후개시방료,채용상규분할,6～15 MV-X선,DT60 Gy,30차,6주완성.치료조재방화료기간가용삼기부정주사액250 ml,매천1차,21 d위1개주기,2개주기위1개료정.대조조급여일반지지치료.량조환자재방료결속후1주재용NP방안화료2개주기.비교량조적림상료효、불량반응、생활질량、면역공능.결과 치료조완전완해솔、부분완해솔、총유효솔분별위16.7%、60.0%、76.7%;대조조분별위10.7%、50.0%、60.7%.치료조0.5、1、2년생존솔분별위96.7%、65.2%、45.0%;대조조분별위89.3%、48.0%、35.1%.량조비교차이무통계학의의(P＞0.05).량조환자적림상증상、생활질량、면역공능개선정황비교,차이유통계학의의(P＜0.05).결론 방화료가삼기부정주사액종합치료NSCLC능개선환자적림상증상、생활질량、면역공능화감경방화료적불량반응,단미능제고환자적생존솔.
Objective To evaluate the response and toxicity of the chemo-radiotherapy assisted with Shenqi Fuzheng injection(SFI)in non-small-cell lung cancer(NSCLC).Methods 58 cases of NSCLC(from Jun.2004 to Dec.2006)were divided at random into two groups.30 cases(trial group)were given chemo-radiotherapy with Shenqi Fuzheng injection while another 28 cases(control group)only chemo-radiotherapy.The radiotherapy was carried out between two cycles of induction chemotherapy with NVB 25 mg/m2 d1,8,DDP 30 mg/m2 d1-3.The radiation dose was 60 Gy/30 f/6 W.Shenqi Fuzheng injection was used in 250 ml/d,for 21days as one cycle and after 7 day intervals, given another one cycle.The cycles of same regimen chemotherapy were given again after one week when the radiotherapy had been completed.Results Shortterm therapeutic effectiveness.the rates of complete remission and partial remission as well as the overall effective rates in patients of the trial group and control group were 16.7%,60.0%and 76.7%,and 10.7%,50.0%and 60.7%,respectively,the differences between two groups be not significant(P＞0.05).The 0.5,1,2year survival rates in patients of the trial group and control group were 96.7%,65.2%,45.0%and 89.3%,48.0%,35.0%,respectively,the differences between two groups were not significant(P＞0.05).Shenqi Fuzheng injection was shown to have changes in chemo-radiotherapy effects on clinical symptom,quality of life (QOL)and immune function and toxicity in the treatment of patients with NSCLC(P＜0.05).Conclusion Shenqi Fuzheng injection is shown to have changes in ehemo-radiotherapy effects on clinical symptom,QOL and immune function and toxicity in the treatment of patients with NSCLC,but it could not increase survival rate of the patients.
